Brettly Teague, MD
Ophthalmology · Abilene, TXNPI 1952389967
Payments from drug & device makers
Across 212 payments — averaging $32.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Alcon$1K
- Aerie Pharmaceuticals, Inc.$444
- Bausch & Lomb Americas Inc.$397
- Amgen$221
- Glaukos Corporation$207
- plus $1K from 18 others
What the payments were for
- Consulting fees$1502%
- Food & beverage$6,70196%
- Education$801%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 102 | $3,512 |
| Alcon | 34 | $1,123 |
| Aerie Pharmaceuticals, Inc. | 13 | $444 |
| Bausch & Lomb Americas Inc. | 9 | $397 |
| Amgen(2 entities) | 7 | $221 |
| Glaukos Corporation | 4 | $207 |
| Ivantis, Inc | 3 | $182 |
| Novartis | 9 | $161 |
| Tarsus Pharmaceuticals, Inc. | 3 | $99 |
| Eyepoint US, Inc. | 1 | $96 |
| Sight Sciences, Inc. | 5 | $95 |
| Sun Pharmaceutical Industries Inc. | 3 | $77 |
| Omeros Corporation | 5 | $76 |
| Ocular Therapeutix, Inc. | 3 | $56 |
| Carl Zeiss Meditec USA, Inc. | 1 | $40 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $37 |
| NEW World Medical,inc. | 1 | $26 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $19 |
| Dompe US, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,976 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 120 | $45,722 |
| XiidraLifitegrast | 48 | $44,744 |
| RestasisCyclosporine | 25 | $32,395 |
| LumiganBimatoprost | 93 | $29,542 |
| Prednisolone Acetate | 475 | $19,526 |
| MieboPerfluorohexyloctane/Pf | 25 | $18,547 |
| VyzultaLatanoprostene Bunod | 61 | $17,439 |
| Travoprost | 119 | $15,633 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 74 | $15,629 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 125 | $15,177 |
| TafluprostTafluprost/Pf | 82 | $14,202 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $13,726 |
| Loteprednol Etabonate | 79 | $13,501 |
| RhopressaNetarsudil Mesylate | 35 | $13,161 |
| Brimonidine Tartrate | 161 | $10,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta, Zirgan | $397 | $88,675152 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $3,512 | $80,477166 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $444 | $58,883155 claims |
| AlconSimbrinza | $1,123 | $15,62974 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $37 | $13,50179 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $15 | $3,16014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Abilene
- Sunil PatelAbilene$11.1M
- Seong LeeAbilene$3.3M
- Eric ZavaletaAbilene$2.6M
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.